Loading candles…
Lupin is a pharmaceutical company headquartered in Mumbai with a strong presence in India and a significant role in the global generics market. It operates as an innovation-led transnational firm, developing and commercializing a diverse range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company focuses on several therapeutic areas, including cardiovascular, diabetology, asthma, pediatric, gastrointestinal, anti-infective, and non-steroidal anti-inflammatory drugs (NSAIDs). Lupin serves multiple geographies such as the United States, India, South Africa, Asia Pacific, Latin America, Europe, the Middle East, and other emerging economies.
This page is a live market overview for LUPIN LIMITED (LUPIN) on the NSE. As a listed security, LUPIN LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for LUPIN before placing trades on tick2trade.
As of the latest feed, LUPIN last traded at ₹2,363.5 on NSE, down ₹21.5 (0.90%) from the previous close of ₹2,385. Today's session range is ₹2,346 – ₹2,410, against a 52-week band of ₹1,836.8 – ₹2,529.5. Traded volume today stands at 20.47L shares.
The overview consolidates an interactive price chart with multiple time ranges, a near-the-money option chain snapshot, recent market headlines, upcoming corporate events for LUPIN in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether LUPIN is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for LUPIN LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in LUPIN. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated LUPIN option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Unaudited Results - Q1-FY26 | To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. | 6 Aug 2026 |
| Audited Results - Q4 & FY26 | To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026, and recommend… | 7 May 2026 |
| Unaudited Results - Q3-FY25 | To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025 an… | 12 Feb 2026 |
| Unaudited Results - Q2 & FY25 | To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025. | 6 Nov 2025 |
| Unaudited Results - Q1-FY25 | To consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter Ended June 30, 2025. | 5 Aug 2025 |
| Audited Results - Q4 & FY25 | To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025, and recommend… | 14 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.